复方熊去氧胆酸口服液对大鼠淤胆型肝炎的影响  

Effect of compound ursodeoxycholic acid oral liquid on cholestatic hepatitis in rats

作　　者：尤梅桂 陈同[1] 倪远宁 季晖[1] 

机构地区：[1]中国药科大学药理学教研室,南京210009

出　　处：《中国药科大学学报》2014年第1期102-105,共4页Journal of China Pharmaceutical University

摘　　要：观察复方熊去氧胆酸口服液(C-UDCA)对大鼠肝内胆汁淤积型肝炎的影响。采用灌胃α-萘异硫氰酸酯(ANIT)诱发大鼠淤胆型肝炎模型,检测经口给予C-UDCA后对大鼠胆汁流量、肝功能各项生化指标、肝组织生化指标及肝组织病理形态学的影响。结果显示,C-UDCA能明显减轻ANIT导致的胆管损伤、胆汁淤积和肝细胞损伤。与单方熊去氧胆酸(UDCA)比较,C-UDCA高、中剂量组能显著降低血清丙氨酸转氨酶(ALT)水平、升高肝组织Na+-K+-ATPase、SOD酶活性。提示C-UDCA对ANIT诱导的急性肝内胆汁淤积型肝炎有明显的改善作用,且C-UDCA的作用优于UDCA。The study was designed to investigate the effect of compound ursodeoxycholic acid oral liquid（C-UDCA）on acute intrahepatic cholestasis in rats, which was induced by α-naphthylisothiocyanate（ANIT, 150 mg/kg）. The effects of C-UDCA were examined by serological determination, histological assessment of liver damage and bile excretion experiments. Results demonstrated that the administration of C-UDCA could significantly ameliorate ANIT-induced bile duct injury, cholestasis and hepatocytic damage. Compared with ursodeoxycholic acid（UDCA）, high and mediumdoses of C-UDCA could remarkably reduce the elevated serum levels of alanine aminotransferase（ALT）, while greatly enhancing the activity of Na＋-K＋-ATPase and SOD in liver tissues. All taken together, our data suggested that C-UDCA exhibited a better hepatoprotective effect against ANIT-induced cholestasis than UDCA.

关 键 词：复方熊去氧胆酸口服液 淤胆型肝炎 Α-萘异硫氰酸酯 

分 类 号：R285.5[医药卫生—中药学]